Schering-Plough products approved and launched in Japan
This article was originally published in Scrip
Schering-Ploughhas received formal approval in Japan for its once-daily intranasal steroid Nasonex (mometasone furoate monohydrate), for adult allergic rhinitis. The product will be the first of its type in the country, where the disorder affects 18-23 million people, the company noted. It was recommended in May (Scrip Online, May 29th, 2008) and a launch after price listing is expected in the autumn. Aroglycem (diazoxide) for hyperinsulinism, which received a priority review, has just been launched and is reimbursed at ¥251.80 ($2.36) per 25mg capsule.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.